This company listing is no longer active
ATHX.Q Stock Overview
A biotechnology company, focuses on the research and development activities in the field of regenerative medicine. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Athersys, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.46 |
| 52 Week Low | US$0.000001 |
| Beta | -1.23 |
| 1 Month Change | 0% |
| 3 Month Change | -99.97% |
| 1 Year Change | -100.00% |
| 3 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Athersys: Is Big Pharma Sleeping At The Wheel?
Oct 06Athersys extends exercise period of warrants in connection with recent offering
Sep 23Athersys announces 1-for-25 reverse stock split
Aug 25One Analyst's Revenue Estimates For Athersys, Inc. (NASDAQ:ATHX) Are Surging Higher
Aug 16
Athersys stock falls ~9% after reporting Q2 loss, fall in cash and cash equivalents
Aug 12Kasey Rosado named interim CFO of Athersys
Aug 04Athersys: Dead Man Walking
Jul 25Athersys: Focus On Stroke
May 04Athersys - Hero Or Zero Opportunity
Apr 18Athersys: Near-Term Progress In Stem Cell Phase 3 Trials Could Multiply Shares In 2022
Jan 20Here's Why Athersys (NASDAQ:ATHX) Must Use Its Cash Wisely
Dec 30Athersys: COVID-ARDS Is The Company's Most Important Target
Nov 25Athersys Shares Are Ready To Rumble Following Period Of Turmoil
Aug 30Athersys: Subgroup Analysis As A Masterstroke
Jul 29Here's Why We're Watching Athersys' (NASDAQ:ATHX) Cash Burn Situation
May 28Is Athersys (NASDAQ:ATHX) In A Good Position To Invest In Growth?
Feb 27Shareholder Returns
| ATHX.Q | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -2.6% | 3.9% |
| 1Y | -100.0% | -12.1% | 11.6% |
Return vs Industry: ATHX.Q underperformed the US Biotechs industry which returned 18.7% over the past year.
Return vs Market: ATHX.Q underperformed the US Market which returned 32.8% over the past year.
Price Volatility
| ATHX.Q volatility | |
|---|---|
| ATHX.Q Average Weekly Movement | 6,647.3% |
| Biotechs Industry Average Movement | 11.9% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 4.2% |
Stable Share Price: ATHX.Q's share price has been volatile over the past 3 months.
Volatility Over Time: ATHX.Q's weekly volatility has increased from 3185% to 6647% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 24 | n/a | www.athersys.com |
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company’s lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications.
Athersys, Inc. Fundamentals Summary
| ATHX.Q fundamental statistics | |
|---|---|
| Market cap | US$6.17k |
| Earnings (TTM) | -US$37.51m |
| Revenue (TTM) | US$80.00k |
0.0x
P/S Ratio0.0x
P/E RatioIs ATHX.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATHX.Q income statement (TTM) | |
|---|---|
| Revenue | US$80.00k |
| Cost of Revenue | US$18.78m |
| Gross Profit | -US$18.69m |
| Other Expenses | US$18.81m |
| Earnings | -US$37.51m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.61 |
| Gross Margin | -23,368.75% |
| Net Profit Margin | -46,883.75% |
| Debt/Equity Ratio | -29.6% |
How did ATHX.Q perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/09/25 05:43 |
| End of Day Share Price | 2024/09/25 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Athersys, Inc. is covered by 13 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Gregory Harrison | BofA Global Research |
| Raymond Deacon | Brean Capital |